In the B6.Sle1Yaa model, the CXCR4 peptide inhibitor CTCE-9908 was shown to be very potent at reducing cellular and clinical lupus-linked failures (Wang et al., 2009). Here, CXCR4 is linked to systemic lupus erythematosus.